LGN vs UTHR · rev $2.55B vs P/E 20, rev $1.56B
Legence Corp. Class A Common stock (LGN) versus United Therapeutics Corporation (UTHR) — a side-by-side from cached financials, not a winner call.
Legence Corp. Class A Common stock (LGN) is a engineering & construction company listed on NASDAQ.
United Therapeutics Corporation (UTHR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported LGN revenue for 2025-12-31 was $2.55B. Net income was -$59.8M. Revenue was up 21.5% from 2024-12-31 to 2025-12-31. LGN currently screens at market cap $14.66B.
Latest reported UTHR revenue for 2026-06-30 was $1.56B. Net income was $607.9M. UTHR currently screens at market cap $23.41B and trailing P/E 20.4.
LGN currently screens at market cap $14.66B. UTHR currently screens at market cap $23.41B and trailing P/E 20.4.
Not investment advice. Open the LGN and UTHR stock pages for the full models.
Not investment advice.